Literature DB >> 34378065

Accurate detection of intracranial extension of jugulotympanic paraganglioma by [18F]FDOPA-PET/CT comparing to MRI.

Zahra Jamshidi Araghi1, Shaghayegh Ranjbar1, Michael Paar2, Christian Pirich1, Mohsen Beheshti3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34378065      PMCID: PMC8712304          DOI: 10.1007/s00259-021-05490-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
Jugulotympanic paraganglioma (JTP) is a rare, slow-growing, and usually benign tumor in the jugular foramen [1, 2]. Magnetic resonance imaging (MRI) is used as modality of choice for assessment of JTP [3, 4]. Positron emission tomography–computed tomography (PET/CT) using specific radiotracers (e.g., 68 Ga-DOTA-derivatives) have been performed for localization of multifocal JTP or sites of metastases in malignant tumors [5, 6]. However, the impact of PET/CT using [18F]fluorodihydroxyphenylalanin ([18F]FDOPA), as a specific radiotracer for neuroendocrine tumors (NET), has been less presented in the literature. This particular case presents the superior value of [18F]FDOPA-PET/CT comparing to MRI for depiction of the entire tumor extent in a 53-year-old woman presented with progressive symptoms of vertigo and recurrent tinnitus on the left side for 6 months. Brain MRI reported an osteodestructive mass in the area of the left jugular foramen, extending caudally along the cervical nerve sheath up to the level of hyoid (e–h, arrows). [18F]FDOPA-PET/CT has more accurately defined the intracranial extension of the JPT showing a diffuse, intense tracer uptake in the left jugular foramen, extending to the ipsilateral sigmoid sinus, with tumor growth along the left cerebellar hemisphere up to the lateral aspect of cerebellar tentorium and caudally along the cervical vascular nerve sheath to the level of the hyoid bone (SUV max. 26.3) (a–d. arrows). JPT was approved by histopathology. A physiologic intense [18F]FDOPA-PET/CT uptake was also seen in the gallbladder as excretory organ (a and b, green arrow). The present case emphasizes again on the added value of functional PET imaging using specific radiotracers for the accurate assessment of JPTs, especially when performing in a hybrid PET/MRI setting. a. [18F]FDOPA PET: MIP (Maximum Intensity Projection) anterior view shows intensive tracer uptake along the left cervical and intracranial regions. b. [18F]FDOPA PET/: MIP left lateral c–d. [18F]FDOPA PET (upper row) and fused PET/CT axial images (lower row) show intensive tracer uptake in the area of the left jugular foramen (b–c, black arrow) with cranial extension to the ipsilateral sigmoid sinus, and condylar emissary vein (b–c, red arrow), and an intracranial extension along the left cerebellar hemisphere to the lateral aspect of cerebellar tentorium (b–d, arrowhead). In the caudal dimension, the tumoral tissue shows intensive tracer uptake along the cervical vascular nerve sheath to the level of the hyoid bone. In addition, a small tumoral extension with faint uptake is also seen in the splenius capitis muscle region (b–c, blue arrow). e–h. Magnetic Resonance Imaging (MRI) axial T1 fat suppression with intravenous Gadolinium (e–g), axial T2 TSE (h) demonstrating large tumour expansion centred at the jugular foramen with local bony destruction. Contrast enhancement with typical salt and pepper-appearance with multiple internal flow voids are best seen in T2. Tumoral extension is evident in the sigmoid sinus (f, arrow), the condylar emissary vein via the condylar canal (g, yellow arrow) as well extra cranially along the internal jugular vein with encasement of the internal carotid artery (g–h, white arrow)
  6 in total

Review 1.  Modern nuclear imaging for paragangliomas: beyond SPECT.

Authors:  David Taïeb; Hartmut Neumann; Domenico Rubello; Adil Al-Nahhas; Benjamin Guillet; Elif Hindié
Journal:  J Nucl Med       Date:  2012-02       Impact factor: 10.057

Review 2.  Head and neck imaging: the role of CT and MRI.

Authors:  Franz J Wippold
Journal:  J Magn Reson Imaging       Date:  2007-03       Impact factor: 4.813

3.  European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-29       Impact factor: 9.236

4.  Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.

Authors:  Thomas G Papathomas; Jose Gaal; Eleonora P M Corssmit; Lindsey Oudijk; Esther Korpershoek; Ketil Heimdal; Jean-Pierre Bayley; Hans Morreau; Marieke van Dooren; Konstantinos Papaspyrou; Thomas Schreiner; Torsten Hansen; Per Arne Andresen; David F Restuccia; Ingrid van Kessel; Geert J L H van Leenders; Johan M Kros; Leendert H J Looijenga; Leo J Hofland; Wolf Mann; Francien H van Nederveen; Ozgur Mete; Sylvia L Asa; Ronald R de Krijger; Winand N M Dinjens
Journal:  Eur J Endocrinol       Date:  2013-11-22       Impact factor: 6.664

5.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

Review 6.  Multimodality imaging of paragangliomas of the head and neck.

Authors:  Jarett Thelen; Alok A Bhatt
Journal:  Insights Imaging       Date:  2019-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.